Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNP6QD)

• Drug Name: piribedil Drug Info
• Synonyms: piribedil; 3605-01-4; Trivastal; Trivastan; 2-(4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)pyrimidine; ET 495; ET-495; EU-4200; EU 4200; 2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine; Piribedile [DCIT]; Piribedil [INN:DCF]; Piribedilum [INN-Latin]; UNII-DO22K1PRDJ; DO22K1PRDJ; 1-(2-Pyrimidyl)-4-piperonylpiperazine; 2-(4-Piperonyl-1-piperazinyl)pyrimidine; Pyrimidine, 2-(4-piperonyl-1-piperazinyl)-; OQDPVLVUJFGPGQ-UHFFFAOYSA-N; EINECS 222-764-6; 2-(4-(3,4-Methylenedioxybenzyl)piperazino)pyrimidine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 4850
  ChEBI ID: CHEBI:92833
  CAS Number: CAS 3605-01-4
  TTD Drug ID: DMNP6QD

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[3]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[4]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[5]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[6]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[7]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[8]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[9]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[10]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[11]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[12]

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[13]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[14]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[14]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[15]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[16]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[17]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[18]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[19]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[20]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[20]

Drug(s) Targeting Dopamine D4 receptor (D4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[14]
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[21]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[15]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[17]
L-745,870	DMTGR25	Psychotic disorder	6A20-6A25	Phase 2	[22]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[23]
ABT-724	DMDQVY4	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[24]
Lu-35138	DMQ7A35	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[25]
NGD-94-4	DMZ9WLO	Schizophrenia	6A20	Discontinued in Phase 1	[26]
PD-165167	DMD0GB4	Schizophrenia	6A20	Preclinical	[23]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[27]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[28]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[29]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[30]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[31]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[32]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[33]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[33]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[33]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[33]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[34]
Haloperidol	DM96SE0	Delirium		Approved	[35]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[36]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[37]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[38]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[39]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[40]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[41]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[42]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[43]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[14]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[44]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[45]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[46]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[13]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[47]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[48]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[49]
Treximet	DMU54QB	Migraine	8A80	Approved	[20]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Agonist	[2]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Antagonist	[2]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Antagonist	[2]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[2]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Agonist	[2]
Dopamine D4 receptor (D4R)	TTE0A2F	DRD4_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 49).
• [2] Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
• [3] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [4] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [6] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [7] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [8] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [9] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [10] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [11] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [12] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [13] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [16] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [20] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [21] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [22] Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
• [23] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [24] Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
• [26] I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
• [27] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [28] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [29] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [30] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [31] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [32] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [33] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [34] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [35] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [36] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [37] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [38] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [40] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [41] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [42] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [43] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [44] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [45] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [46] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [47] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [48] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [49] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.